# NCT04601857 (NCT04601857)

> Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

No report yet. It can be ordered.

- Drugs tested: futibatinib plus pembrolizumab
- Indication: advanced or metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04601857
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Taiho Oncology, Inc.
- Conditions: Advanced and Metastatic Urothelial Cancer
- Interventions: Futibatinib; Pembrolizumab
- Enrollment: 43
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on NCT04601857 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04601857